Current medical treatments of dyspepsia and irritable bowel syndrome
- PMID: 20951913
- DOI: 10.1016/j.gtc.2010.08.005
Current medical treatments of dyspepsia and irritable bowel syndrome
Abstract
Dyspepsia is a highly prevalent condition characterized by symptoms originating in the gastroduodenal region without underlying organic disorder. Treatment modalities include acid-suppressive drugs, gastroprokinetic drugs, Helicobacter pylori eradication therapy, tricyclic antidepressants, and psychological therapies. Irritable bowel syndrome is a multifactorial, lower functional gastrointestinal disorder involving disturbances of the brain-gut axis. The pathophysiology provides the basis for pharmacotherapy: abnormal gastrointestinal motor functions, visceral hypersensitivity, psychosocial factors, intraluminal changes, and mucosal immune activation. Medications targeting chronic constipation or diarrhea may also relieve irritable bowel syndrome. Novel approaches to treatment require approval, and promising agents are guanylate cyclase cagonists, atypical benzodiazepines, antibiotics, immune modulators, and probiotics.
Copyright © 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.Prescrire Int. 2009 Apr;18(100):75-9. Prescrire Int. 2009. PMID: 19585728
-
The brain-gut axis in irritable bowel syndrome--clinical aspects.Med Sci Monit. 2004 Jun;10(6):RA125-31. Epub 2004 Jun 1. Med Sci Monit. 2004. PMID: 15173682 Review.
-
A review of irritable bowel syndrome and an update on therapeutic approaches.Expert Opin Pharmacother. 2008 May;9(7):1129-43. doi: 10.1517/14656566.9.7.1129. Expert Opin Pharmacother. 2008. PMID: 18422471 Review.
-
Phytotherapy for functional dyspepsia: a review of the clinical evidence for the herbal preparation STW 5.Phytomedicine. 2006;13 Suppl 5:114-21. doi: 10.1016/j.phymed.2006.03.022. Epub 2006 Sep 15. Phytomedicine. 2006. PMID: 16978851 Review.
-
Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.J Physiol Pharmacol. 2011 Dec;62(6):591-9. J Physiol Pharmacol. 2011. PMID: 22314561 Review.
Cited by
-
Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial.Medicina (Kaunas). 2020 Jul 8;56(7):339. doi: 10.3390/medicina56070339. Medicina (Kaunas). 2020. PMID: 32650518 Free PMC article. Clinical Trial.
-
Efficacy of prebiotics and probiotics for functional dyspepsia: A systematic review and meta-analysis.Medicine (Baltimore). 2020 Feb;99(7):e19107. doi: 10.1097/MD.0000000000019107. Medicine (Baltimore). 2020. PMID: 32049821 Free PMC article.
-
Overlap in patients with dyspepsia/functional dyspepsia.J Neurogastroenterol Motil. 2014 Oct 30;20(4):447-57. doi: 10.5056/jnm14080. Epub 2014 Sep 26. J Neurogastroenterol Motil. 2014. PMID: 25257470 Free PMC article.
-
Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.World J Gastroenterol. 2014 Jul 21;20(27):8898-909. doi: 10.3748/wjg.v20.i27.8898. World J Gastroenterol. 2014. PMID: 25083062 Free PMC article. Review.
-
Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation.United European Gastroenterol J. 2013 Feb;1(1):7-20. doi: 10.1177/2050640612474446. United European Gastroenterol J. 2013. PMID: 24917937 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
